Cancer Biology & Genetics Program
The Tuomas Tammela Lab
The Tammela lab is interested in understanding the remarkable phenotypic heterogeneity of cancer cells within tumors. We approach this question using a combination of sophisticated genetically engineered mouse models, single cell transcriptomics, tracing and ablation of distinct tumor cell lineages, CRISPR-mediated gene regulation, and advanced imaging techniques. We utilize the exceptional resources developed by our MSK collaborators, such as organoids and xenografts, for the translation of our findings into new treatments for human cancer. Our goal is to discover pathways that drive distinct cellular phenotypes and to develop new therapeutic concepts aimed at reducing cellular heterogeneity in tumors.
Tammela T, Sanchez-Rivera FJ, Malli-Cetinbas N, Joshi NS, Helenius K, Park YK, Azimi R, Wu K, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ÖH, Xue W, Katajisto P, Bhutkar A, and Jacks T. A Wnt-producing niche maintains proliferative potential and drives tumor progression in lung adenocarcinoma. Nature, 545:355-359 (2017).
Roper J*, Tammela T*, Cetinbas N, Akkad A, Almeqdadi M, Wu K, Sánchez-Rivera F, Rickelt S, Park Y, Liang X, Oberli M, Eng G, Roghanian A, Azimi R, Kedrin D., Neupane R., Beyaz S., Sicinska E.T., Bass A., Suarez Y., Yoo J., Chen L., Taylor M.S., Zukerberg L., Katajisto P., Lees J., Deshpande V., Chen J., Hynes R.O., Langer R., Bhutkar A.J., Jacks T., Yilmaz. Ö.H. Epithelial genome editing and orthotopic transplantation models of sequential mutagenesis in colorectal cancer. Nature Biotechnology, 3:569–576 (2017).
Tuomas Tammela, MD, PhD
- Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung, pancreatic and colon cancers.
- Massachusetts Institute of Technology: Postdoctoral Fellowship
- University of Helsinki, Finland: MD, PhD
- NCI/NIH K99 Transition to Independence Award
- European Research Council Starter Grant
- Josie Robertson Young Investigator Award
- The Werner Risau Prize
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Tuomas Tammela discloses the following relationships and financial interests:
Regeneron Pharmaceuticals, Inc.
Provision of Services
University of Helsinki
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.